deferoxamine has been researched along with HbS Disease in 81 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine." | 10.23 | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024) |
| " The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited." | 9.51 | Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022) |
| "To examine the efficacy of deferasirox (DFX) by comparison with deferoxamine (DFO) in managing iron overload in patients with sickle cell anaemia (SCA)." | 9.22 | Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis. ( Qadah, T, 2022) |
| "Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload." | 9.12 | A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. ( Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F, 2007) |
| "To assess the effectiveness and safety of oral deferasirox in people with SCD and secondary iron overload." | 8.86 | Deferasirox for managing transfusional iron overload in people with sickle cell disease. ( Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Niemeyer, C; Rücker, G, 2010) |
| "Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload." | 7.74 | Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. ( Baladi, JF; Coates, TD; Delea, TE; Hagiwara, M; Phatak, PD; Thomas, SK, 2008) |
| " The resultant iron overload must be treated with chelation therapy using deferoxamine." | 7.69 | Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy. ( Berdon, WE; Hurlet-Jensen, A; Piomelli, S; Ruzal-Shapiro, C; Sheth, S, 1997) |
| "Transfusion-induced hemosiderosis is a serious and potentially life-threatening complication for some patients with sickle cell anemia." | 6.67 | Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. ( Dixon, DJ; Hambidge, KM; Lane, PA; Mellman, DL; Peterson, VM; Silliman, CC, 1993) |
| "This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine." | 6.23 | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024) |
| " The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited." | 5.51 | Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022) |
| "To examine the efficacy of deferasirox (DFX) by comparison with deferoxamine (DFO) in managing iron overload in patients with sickle cell anaemia (SCA)." | 5.22 | Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis. ( Qadah, T, 2022) |
| " We report baseline LIC results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients." | 5.20 | Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. ( Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC, 2015) |
| "We report a prospective, randomized, Phase II study of deferasirox and deferoxamine (DFO) in sickle cell disease patients with transfusional iron overload, with all patients continuing on deferasirox after 24 weeks, for up to 2 years." | 5.17 | Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. ( Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y, 2013) |
| "Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload." | 5.12 | A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. ( Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F, 2007) |
| "To compare the efficacy and safety of desferrioxamine (DFO), deferiprone (DFP), deferasirox (DFX) and silymarin in patients with either thalassemia or sickle cell disorder through network meta-analysis." | 4.98 | Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. ( Sivaramakrishnan, G; Sridharan, K, 2018) |
| "To assess the effectiveness and safety of oral deferasirox in people with SCD and secondary iron overload." | 4.86 | Deferasirox for managing transfusional iron overload in people with sickle cell disease. ( Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Niemeyer, C; Rücker, G, 2010) |
| "Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload." | 3.74 | Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. ( Baladi, JF; Coates, TD; Delea, TE; Hagiwara, M; Phatak, PD; Thomas, SK, 2008) |
| " In thalassemia major patients, combined therapy with desferrioxamine and deferiprone has maximized tissue iron removal and may reduce the overall occurrence of hemosiderotic heart failure." | 3.73 | Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia. ( Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Moyssakis, I; Polonifi, K; Tsironi, M, 2005) |
| " The resultant iron overload must be treated with chelation therapy using deferoxamine." | 3.69 | Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy. ( Berdon, WE; Hurlet-Jensen, A; Piomelli, S; Ruzal-Shapiro, C; Sheth, S, 1997) |
| " Deferoxamine-induced urinary excretion of iron was considerably less than that reported in patients with thalassemia major who were receiving regular blood transfusions." | 3.66 | Iron burden in sickle cell anemia. ( O'Brien, RT, 1978) |
| "Transfusion-induced hemosiderosis is a serious and potentially life-threatening complication for some patients with sickle cell anemia." | 2.67 | Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. ( Dixon, DJ; Hambidge, KM; Lane, PA; Mellman, DL; Peterson, VM; Silliman, CC, 1993) |
| "Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints." | 2.44 | Chelation therapy for iron overload. ( Barton, JC, 2007) |
| "Despite the clinical use of deferoxamine for more than a quarter of a century, pharmacokinetic studies are few and have not been performed explicitly in patients with sickle cell disorders." | 2.41 | Deferoxamine pharmacokinetics. ( Porter, JB, 2001) |
| "Sickle cell anemia affects 100,000 African Americans." | 1.39 | Sickle cell anemia: the impact of discovery, politics, and business. ( Conley, E; Doye, AA; Gwathmey, JK; Xie, LH, 2013) |
| "For chronic conditions such as thalassemia major, even when oral chelation therapy is available, support by an integrated team including a clinical psychologist and nurse specialist working with the treatment center is recommended to achieve optimal results." | 1.37 | Challenges of adherence and persistence with iron chelation therapy. ( El-Beshlawy, A; Evangeli, M; Porter, JB, 2011) |
| " This regimen is safe and may be an option for poorly compliant patients with significant iron overload." | 1.36 | Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. ( Abboud, MR; Disco, D; Holloman, D; Jackson, S; Kalpatthi, R; Kane, I; Laver, JH; Peters, B; Rackoff, E, 2010) |
| "The stroke was ischemic in all individuals and the first cerebrovascular event occurred before 6 years of age; 3 patients had recurrence of stroke despite prophylactic blood transfusion therapy and both cerebral hemispheres were affected in 4 patients." | 1.35 | Stroke in patients with sickle cell disease: clinical and neurological aspects. ( Ciasca, SM; Moura-Ribeiro, MV; Oliveira, CC, 2008) |
| "A 17-year-old patient with sickle cell-beta thalassemia undergoing treatment with home iron chelation therapy inadvertently received ten times the recommended dose of intravenous deferoxamine." | 1.32 | Acute renal failure following deferoxamine overdose. ( Flynn, JT; Levine, JE; Prasannan, L, 2003) |
| "Management of these patients requires proper dosing of desferrioxamine and transfusion therapy, along with regular monitoring of body iron burden and hemoglobin." | 1.30 | Desferrioxamine ototoxicity in an adult transfusion-dependent population. ( Alberti, PW; Chiodo, AA; Francombe, WH; Sher, GD; Tyler, B, 1997) |
| " The authors have previously demonstrated that in vitro exposure of mononuclear cells to DFX decreases the bioavailability of tumour necrosis factor alpha (TNF-alpha) which has a stimulatory effect on HIV-1 replication." | 1.30 | Reduction of tumour necrosis factor alpha expression and signalling in peripheral blood mononuclear cells from patients with thalassaemia or sickle cell anaemia upon treatment with desferrioxamine. ( Baud, L; Bellocq, A; Cadranel, J; Fouqueray, B; Girot, R; Israël-Biet, D; Kanfer, A; Perez, J, 1999) |
| "Deferoxamine therapy was withheld, and antibiotic therapy was administered with subsequent clinical improvement." | 1.29 | Yersinia enterocolitica infection in a patient with sickle cell disease after exposure to chitterlings. ( Casella, JF; Nataro, JP; Stoddard, JJ; Wechsler, DS, 1994) |
| "To determine the frequency of eye and auditory complications and their relationship to drug dosage and iron stores in patients receiving deferoxamine, we studied 52 regularly transfused patients who received deferoxamine by subcutaneous or intravenous infusion in doses from 26 to 136 mg/kg/day, and whose serum ferritin levels of 185 to 17,775 micrograms/L reflected a wide range of iron stores." | 1.28 | Vision and hearing during deferoxamine therapy. ( Cohen, A; Konkle, DF; Martin, M; Mizanin, J; Schwartz, E, 1990) |
| " The dosage and the route of administration (IV, IM, SC) were adapted to the amount of iron transfused and to the nature of the disease." | 1.28 | [Treatment of post-transfusion iron overload by deferoxamine]. ( de Montalembert, M; Girot, R; Hannedouche, T; Llados, A, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (23.46) | 18.7374 |
| 1990's | 22 (27.16) | 18.2507 |
| 2000's | 17 (20.99) | 29.6817 |
| 2010's | 19 (23.46) | 24.3611 |
| 2020's | 4 (4.94) | 2.80 |
| Authors | Studies |
|---|---|
| Kwiatkowski, JL | 4 |
| Hamdy, M | 2 |
| El-Beshlawy, A | 3 |
| Ebeid, FSE | 2 |
| Badr, M | 1 |
| Alshehri, A | 1 |
| Kanter, J | 2 |
| Inusa, B | 2 |
| Adly, AAM | 1 |
| Williams, S | 2 |
| Kilinc, Y | 1 |
| Lee, D | 2 |
| Tricta, F | 2 |
| Elalfy, MS | 2 |
| Qadah, T | 1 |
| Geneen, LJ | 1 |
| Dorée, C | 2 |
| Estcourt, LJ | 2 |
| Veríssimo, MPA | 1 |
| Temin, NT | 1 |
| Fradette, C | 1 |
| Ballas, SK | 2 |
| Zeidan, AM | 1 |
| Duong, VH | 1 |
| DeVeaux, M | 1 |
| Heeney, MM | 2 |
| Sridharan, K | 1 |
| Sivaramakrishnan, G | 1 |
| Fortin, PM | 1 |
| Fisher, SA | 1 |
| Madgwick, KV | 1 |
| Trivella, M | 1 |
| Hopewell, S | 1 |
| Hider, RC | 1 |
| Hoffbrand, AV | 2 |
| Vichinsky, E | 5 |
| Torres, M | 1 |
| Minniti, CP | 1 |
| Barrette, S | 1 |
| Habr, D | 1 |
| Zhang, Y | 1 |
| Files, B | 3 |
| Xie, LH | 1 |
| Doye, AA | 1 |
| Conley, E | 1 |
| Gwathmey, JK | 1 |
| Calvaruso, G | 1 |
| Vitrano, A | 1 |
| Di Maggio, R | 1 |
| Ballas, S | 1 |
| Steinberg, MH | 1 |
| Rigano, P | 1 |
| Sacco, M | 1 |
| Telfer, P | 1 |
| Renda, D | 1 |
| Barone, R | 1 |
| Maggio, A | 2 |
| Wood, JC | 2 |
| Pressel, S | 1 |
| Rogers, ZR | 1 |
| Odame, I | 1 |
| Lee, MT | 2 |
| Owen, WC | 1 |
| Cohen, AR | 4 |
| St Pierre, T | 1 |
| Schultz, WH | 2 |
| Davis, BR | 1 |
| Ware, RE | 2 |
| Adamkiewicz, TV | 1 |
| Abboud, MR | 2 |
| Paley, C | 1 |
| Olivieri, N | 1 |
| Kirby-Allen, M | 1 |
| Casella, JF | 2 |
| Alvarez, OA | 1 |
| Barredo, JC | 1 |
| Iyer, RV | 1 |
| Kutlar, A | 1 |
| McKie, KM | 1 |
| McKie, V | 1 |
| Odo, N | 1 |
| Gee, B | 2 |
| Woods, GM | 1 |
| Coates, T | 3 |
| Wang, W | 2 |
| Adams, RJ | 1 |
| Inati, A | 2 |
| Musallam, KM | 2 |
| Taher, AT | 2 |
| Meerpohl, JJ | 1 |
| Antes, G | 1 |
| Rücker, G | 1 |
| Fleeman, N | 1 |
| Niemeyer, C | 1 |
| Bassler, D | 1 |
| Khoriaty, E | 1 |
| Cario, H | 1 |
| Grosse, R | 1 |
| Janssen, G | 1 |
| Jarisch, A | 1 |
| Meerpohl, J | 1 |
| Strauss, G | 1 |
| Kalpatthi, R | 1 |
| Peters, B | 1 |
| Kane, I | 1 |
| Holloman, D | 1 |
| Rackoff, E | 1 |
| Disco, D | 1 |
| Jackson, S | 1 |
| Laver, JH | 1 |
| Carrara, P | 1 |
| Balocco, M | 1 |
| Pinto, V | 1 |
| Olcese, F | 1 |
| Soldà, A | 1 |
| Strada, P | 1 |
| Forni, GL | 3 |
| Brittenham, GM | 1 |
| Jordan, LB | 1 |
| Vekeman, F | 1 |
| Sengupta, A | 1 |
| Corral, M | 1 |
| Guo, A | 1 |
| Duh, MS | 1 |
| Porter, JB | 2 |
| Evangeli, M | 1 |
| Armstrong, EP | 1 |
| Skrepnek, GH | 1 |
| Sasane, M | 1 |
| Snodgrass, SM | 1 |
| Ruivard, M | 1 |
| Prasannan, L | 1 |
| Flynn, JT | 1 |
| Levine, JE | 1 |
| D'Amico, G | 1 |
| Morabito, A | 1 |
| Treadwell, MJ | 2 |
| Law, AW | 1 |
| Sung, J | 1 |
| Hackney-Stephens, E | 1 |
| Quirolo, K | 1 |
| Murray, E | 1 |
| Glendenning, GA | 1 |
| Berdoukas, V | 1 |
| Bohane, T | 1 |
| Tobias, V | 1 |
| De Silva, K | 1 |
| Fraser, I | 1 |
| Aessopos, A | 2 |
| Lindeman, R | 1 |
| Wood, KC | 1 |
| Hebbel, RP | 3 |
| Granger, DN | 1 |
| Tsironi, M | 1 |
| Polonifi, K | 1 |
| Deftereos, S | 1 |
| Farmakis, D | 1 |
| Andriopoulos, P | 1 |
| Moyssakis, I | 1 |
| Onyekwere, O | 2 |
| Porter, J | 2 |
| Swerdlow, P | 2 |
| Eckman, J | 1 |
| Lane, P | 2 |
| Hassell, K | 1 |
| Kelly, P | 1 |
| Wilson, F | 1 |
| Bernaudin, F | 1 |
| Okpala, I | 1 |
| Ressayre-Djaffer, C | 1 |
| Alberti, D | 1 |
| Holland, J | 1 |
| Marks, P | 2 |
| Fung, E | 1 |
| Fischer, R | 2 |
| Mueller, BU | 2 |
| Barton, JC | 1 |
| Delea, TE | 1 |
| Hagiwara, M | 1 |
| Thomas, SK | 1 |
| Baladi, JF | 2 |
| Phatak, PD | 1 |
| Coates, TD | 1 |
| Oliveira, CC | 1 |
| Ciasca, SM | 1 |
| Moura-Ribeiro, MV | 1 |
| Pakbaz, Z | 1 |
| Coïc, L | 1 |
| Rofail, D | 1 |
| Abetz, L | 1 |
| Thompson, RB | 1 |
| Owen, DM | 1 |
| Bell, WN | 1 |
| Gyftaki, H | 1 |
| Kesse-Elias, M | 1 |
| Constantoulakis, M | 1 |
| Malamos, B | 1 |
| Falk, RJ | 1 |
| Mattern, WD | 1 |
| Lamanna, RW | 1 |
| Gitelman, HJ | 1 |
| Parker, NC | 1 |
| Cross, RE | 1 |
| Rastall, JR | 1 |
| Collins, AF | 1 |
| Fassos, FF | 1 |
| Stobie, S | 1 |
| Lewis, N | 1 |
| Shaw, D | 1 |
| Fry, M | 1 |
| Templeton, DM | 1 |
| McClelland, RA | 1 |
| Koren, G | 2 |
| Olivieri, NF | 3 |
| Stoddard, JJ | 1 |
| Wechsler, DS | 1 |
| Nataro, JP | 1 |
| Graubner, UB | 1 |
| Schmidt, P | 1 |
| Haas, RJ | 1 |
| Loesberg, AC | 1 |
| Martin, WB | 1 |
| Blei, F | 1 |
| Puder, DR | 1 |
| Silliman, CC | 1 |
| Peterson, VM | 1 |
| Mellman, DL | 1 |
| Dixon, DJ | 1 |
| Hambidge, KM | 1 |
| Lane, PA | 1 |
| Adams, DM | 1 |
| Kinney, TR | 1 |
| Araujo, A | 1 |
| Kosaryan, M | 1 |
| MacDowell, A | 1 |
| Wickens, D | 1 |
| Puri, S | 1 |
| Wonke, B | 2 |
| Shalev, O | 1 |
| McLean, TW | 1 |
| Kurth, S | 1 |
| Chiodo, AA | 1 |
| Alberti, PW | 1 |
| Sher, GD | 1 |
| Francombe, WH | 2 |
| Tyler, B | 1 |
| Shilalukey, K | 1 |
| Kaufman, M | 1 |
| Bradley, S | 1 |
| Amankwah, K | 1 |
| Goldberg, E | 1 |
| Shear, N | 1 |
| Sheth, S | 1 |
| Ruzal-Shapiro, C | 1 |
| Hurlet-Jensen, A | 1 |
| Piomelli, S | 2 |
| Berdon, WE | 1 |
| Bellocq, A | 1 |
| Israël-Biet, D | 1 |
| Cadranel, J | 1 |
| Perez, J | 1 |
| Fouqueray, B | 1 |
| Kanfer, A | 1 |
| Girot, R | 2 |
| Baud, L | 1 |
| Wayne, AS | 1 |
| Schoenike, SE | 1 |
| Pegelow, CH | 1 |
| Weissman, L | 1 |
| Powars, DR | 1 |
| Wong, WY | 1 |
| Vachon, LA | 1 |
| Cohen, A | 4 |
| Schwartz, E | 7 |
| O'Brien, RT | 1 |
| Moore, RB | 1 |
| Hulgan, TM | 1 |
| Green, JW | 1 |
| Jenkins, LD | 1 |
| Martin, MB | 1 |
| Silber, JH | 1 |
| Kim, HC | 1 |
| Ohene-Frempong, K | 1 |
| Repka, T | 1 |
| Davies, SC | 1 |
| Hartley, A | 2 |
| Davies, M | 1 |
| Rice-Evans, C | 3 |
| Pierron, H | 1 |
| Gillet, R | 1 |
| Perrimond, H | 1 |
| Broudeur, JC | 1 |
| Soudry, G | 1 |
| Martin, M | 2 |
| Mizanin, J | 3 |
| Konkle, DF | 1 |
| Davies, MJ | 1 |
| de Montalembert, M | 1 |
| Llados, A | 1 |
| Hannedouche, T | 1 |
| Wang, WC | 1 |
| Ahmed, N | 1 |
| Hanna, M | 2 |
| Pippard, MJ | 1 |
| Gaffney, JW | 1 |
| Bierman, FZ | 1 |
| Donnelly, CM | 1 |
| Sutton, M | 1 |
| Gersony, WM | 1 |
| Ahmed, NK | 1 |
| Omorphos, SC | 1 |
| Baysal, E | 1 |
| Khutsishvili, GE | 1 |
| Wöhler, F | 1 |
| Mainzer, K | 1 |
| Kirimlidis, S | 1 |
| Philippidis, P | 1 |
| Drossos, C | 1 |
| Economidis, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias[NCT02041299] | Phase 4 | 230 participants (Actual) | Interventional | 2014-04-17 | Terminated (stopped due to Difficulties with additional recruitment as pool of potential patients was exhausted, and sufficient information for determination of study outcome measure was already obtained) | ||
| [NCT00000592] | Phase 3 | 0 participants | Interventional | 1994-07-31 | Completed | ||
| [NCT00006182] | Phase 3 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.[NCT01892644] | Phase 2 | 50 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to Failure to recruit patients with hemochromatosis to the Deferasirox arm) | ||
| A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis[NCT00067080] | Phase 2 | 195 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Clinical Importance of Treating Iron Overload in Sickle Cell Disease[NCT00981370] | Phase 3 | 1 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to 1 consented patient never started on study drug, lost to follow up) | ||
| A Trial of Oral Nifedipine for the Treatment of Iron Overload[NCT00712738] | Phase 1 | 6 participants (Actual) | Interventional | 2008-06-20 | Completed | ||
| Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia[NCT00061568] | Phase 1/Phase 2 | 150 participants (Anticipated) | Interventional | 2004-07-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiac iron is measured by MRI in milliseconds (ms). A score of less than 20 ms is indicative of cardiac iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | milliseconds (Least Squares Mean) |
|---|---|
| Deferiprone | -0.022068 |
| Deferoxamine | -0.021773 |
LIC was measured by MRI. A score >7 mg/g dw is indicative of iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | mg of iron per gram of liver dry weight (Least Squares Mean) |
|---|---|
| Deferiprone | -4.13 |
| Deferoxamine | -4.38 |
Serum ferritin provides a measure of iron level in the blood. Normal levels of serum ferritin are under 300 µg/L for females and 400 µg/L for males. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | micrograms per liter (Least Squares Mean) |
|---|---|
| Deferiprone | -385.83 |
| Deferoxamine | -760.89 |
Adult patients completed the SF-36 questionnaire and minors completed the CHQ-PF50. These questionnaires yield a profile of functional health and well-being, based on 8 scales of physical and mental health measures: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and Mental Health (MH), and summary scores are produced for physical well-being and mental well-being. The summaries are scored from 0-100, with higher scores reflecting better outcomes. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| SF-36 Physical Summary | SF-36 Mental Summary | CHQ-PF50 Physical Summary | CHQ-PF50 Psychosocial Summary | |
| Deferiprone | 43.1 | 44.7 | 29.3 | 42.5 |
| Deferoxamine | 43.0 | 40.9 | 30.5 | 41.3 |
15 reviews available for deferoxamine and HbS Disease
| Article | Year |
|---|---|
Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron | 2022 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Anemia, Sickle Cell; Chelating Agents; Chelation Therapy; Child; Deferoxamine; Drug-Related Side Eff | 2023 |
The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Deferiprone; Deferoxamine; Humans; Iron Ch | 2018 |
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; H | 2018 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Defer | 2018 |
The Role of Deferiprone in Iron Chelation.
Topics: Anemia, Sickle Cell; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Erythr | 2018 |
Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusio | 2010 |
Iron-chelating therapy for transfusional iron overload.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyt | 2011 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Ir | 2013 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferipron | 2007 |
[Congenital anemia].
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; Child, Preschool; Combined Modality | 1994 |
Yersinia enterocolitica bacteremia in a chronically transfused patient with sickle cell anemia. Case report and review of the literature.
Topics: Adolescent; Anemia, Sickle Cell; Bacteremia; Blood Transfusion; Ceftriaxone; Deferoxamine; Disease S | 1993 |
Deferoxamine pharmacokinetics.
Topics: Anemia, Sickle Cell; Deferoxamine; Drug Administration Routes; Ferric Compounds; Humans; Iron Chelat | 2001 |
The management of haemoglobinopathies.
Topics: Adolescent; Anemia, Sickle Cell; Bone Marrow Transplantation; Chelation Therapy; Child; Child, Presc | 1991 |
Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.
Topics: Anemia, Sickle Cell; Ascorbic Acid; Deferoxamine; Drug Administration Schedule; Forecasting; Humans; | 1987 |
9 trials available for deferoxamine and HbS Disease
| Article | Year |
|---|---|
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron | 2022 |
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Humans; Iron; Iron C | 2024 |
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therap | 2013 |
Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Child; Deferiprone; Deferoxamine; Female; | 2014 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Pre | 2015 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Topics: Absenteeism; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Child, Pre | 2008 |
Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Deferoxamine; Dose-Response Relationship, Drug; Double-Blind | 1993 |
57 other studies available for deferoxamine and HbS Disease
| Article | Year |
|---|---|
Sickle cell anemia: the impact of discovery, politics, and business.
Topics: Anemia, Sickle Cell; Animals; Cost Savings; Deferoxamine; Disease Models, Animal; Drug Delivery Syst | 2013 |
Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2010 |
Iron chelation therapy for patients with sickle cell disease and iron overload.
Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferip | 2010 |
[Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia].
Topics: Anemia, Aplastic; Anemia, Diamond-Blackfan; Anemia, Dyserythropoietic, Congenital; Anemia, Sickle Ce | 2010 |
Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
Topics: Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Aspartate Aminotransferases; Chelation | 2010 |
Manual erythroexchange for chronic transfusion therapy in patients with sickle cell syndromes unresponsive to hydroxyurea: a long-term follow-up.
Topics: Anemia, Sickle Cell; Blood Transfusion, Autologous; Deferoxamine; Erythrocyte Transfusion; Humans; H | 2010 |
Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; | 2012 |
Challenges of adherence and persistence with iron chelation therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasir | 2011 |
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Child; Deferasiro | 2013 |
Acute renal failure following deferoxamine overdose.
Topics: Acute Kidney Injury; Adolescent; Anemia, Sickle Cell; beta-Thalassemia; Deferoxamine; Drug Overdose; | 2003 |
Independent clinical trials.
Topics: Anemia, Sickle Cell; Deferiprone; Deferoxamine; Drug Industry; Financial Support; Humans; Multicente | 2004 |
Barriers to adherence of deferoxamine usage in sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Caregivers; Chelation Therapy; Child; Child, Preschool; Cognition D | 2005 |
Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy.
Topics: Adolescent; Adult; Anemia, Diamond-Blackfan; Anemia, Sickle Cell; beta-Thalassemia; Biopsy; Blood Tr | 2005 |
Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice.
Topics: Allopurinol; Anemia, Sickle Cell; Animals; Bone Marrow Transplantation; Brain; Deferoxamine; Endothe | 2005 |
Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferiprone; Def | 2005 |
Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Cardiomyopathies; Chelation Therapy; Child; Child, Preschool | 2008 |
Stroke in patients with sickle cell disease: clinical and neurological aspects.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Child; Deferoxamine; Female; Humans; Inte | 2008 |
Desferal therapy in iron storage disease.
Topics: Adolescent; Adult; Anemia, Aplastic; Anemia, Sickle Cell; Deferoxamine; Female; Hemochromatosis; Hem | 1967 |
Radioactive iron (59Fe) excretion through the urine and feces after intravenous iron-59 administration in congenital hemolytic anemias.
Topics: Anemia, Sickle Cell; Deferoxamine; Feces; Humans; Iron Isotopes; Thalassemia | 1967 |
Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine.
Topics: Adult; Anemia, Sickle Cell; Deferoxamine; Female; Humans; Injections, Intravenous; Iron; Kidney Fail | 1983 |
Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Child; Deferiprone; Deferoxamine; Dose-Respon | 1994 |
Yersinia enterocolitica infection in a patient with sickle cell disease after exposure to chitterlings.
Topics: Anemia, Sickle Cell; Animals; Child; Deferoxamine; Female; Food Microbiology; Humans; Intestines; Sw | 1994 |
Altered biodistribution of Ga-67 citrate in an iron-overloaded patient with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Bone and Bones; Citrates; Citric Acid; Deferoxamine; | 1994 |
Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients.
Topics: Adolescent; Adult; Anemia, Dyserythropoietic, Congenital; Anemia, Sickle Cell; Chelation Therapy; Ch | 1996 |
A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Deferoxamine; Drug Delivery Systems; Femal | 1996 |
Extremely high avidity association of Fe(III) with the sickle red cell membrane.
Topics: Anemia, Sickle Cell; Binding, Competitive; Deferoxamine; Erythrocyte Membrane; Humans; Iron; Iron Ch | 1996 |
Pelvic osteomyelitis in a sickle-cell patient receiving deferoxamine.
Topics: Adolescent; Anemia, Sickle Cell; Chelation Therapy; Deferoxamine; Humans; Ilium; Injections, Subcuta | 1996 |
Desferrioxamine ototoxicity in an adult transfusion-dependent population.
Topics: Adult; Aged; Anemia, Sickle Cell; Audiometry; beta-Thalassemia; Deferoxamine; Drug Monitoring; Fanco | 1997 |
Counseling sexually active teenagers treated with potential human teratogens.
Topics: Adolescent; Adolescent Behavior; Anemia, Sickle Cell; beta-Thalassemia; Contraception Behavior; Coun | 1997 |
Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy.
Topics: Adolescent; Anemia, Sickle Cell; Catheterization, Central Venous; Chelation Therapy; Deferoxamine; F | 1997 |
Reduction of tumour necrosis factor alpha expression and signalling in peripheral blood mononuclear cells from patients with thalassaemia or sickle cell anaemia upon treatment with desferrioxamine.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Cells, Cultured; Culture Media, Conditione | 1999 |
Financial analysis of chronic transfusion for stroke prevention in sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Cost-Benefit Analysis; Deferoxamine; Erythrocyte Transfusion | 2000 |
Progression of iron overload in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Biopsy, Needle; Child; Child, Preschool; Cohort Studies; Def | 2001 |
Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Caregivers; Child; Data | 2001 |
Incomplete cerebral infarctions are not silent.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Bone Marrow Transplantation; Brain Damage, Chr | 2001 |
Iron chelation therapy in sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Ascorbic Acid; Blood Transfusion; Child; Deferoxamine; Erythrocyte | 1979 |
Excretion of iron in response to deferoxamine in sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Ascorbic Acid; Blood Transfusion; Child; Deferoxamine; Eryth | 1978 |
Iron burden in sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Body Burden; Child; Child, Preschool; Deferoxamine; Ferritin | 1978 |
Increased susceptibility of the sickle cell membrane Ca2+ + Mg(2+)-ATPase to t-butylhydroperoxide: protective effects of ascorbate and desferal.
Topics: Anemia, Sickle Cell; Ascorbic Acid; Ca(2+) Mg(2+)-ATPase; Calcium-Transporting ATPases; Calmodulin; | 1992 |
A modified transfusion program for prevention of stroke in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Cerebral Hemorrhage; Cerebrovascular Diso | 1992 |
Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents.
Topics: Anemia, Sickle Cell; Ascorbic Acid; Deferoxamine; Erythrocyte Membrane; Free Radicals; Glutathione; | 1991 |
Desferrioxamine as a lipid chain-breaking antioxidant in sickle erythrocyte membranes.
Topics: Anemia, Sickle Cell; Antioxidants; Deferoxamine; Electron Spin Resonance Spectroscopy; Erythrocyte M | 1990 |
[Yersinia infection and hemoglobin disorder. Apropos of 4 cases].
Topics: Anemia, Sickle Cell; Child; Deferoxamine; Female; Humans; Iron; Male; Thalassemia; Yersinia enteroco | 1990 |
Current treatment of Cooley's anemia. Intravenous chelation therapy.
Topics: Adult; Anemia, Sickle Cell; Deferoxamine; Female; Ferritins; Humans; Infusions, Intravenous; Thalass | 1990 |
Vision and hearing during deferoxamine therapy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Chelation Therapy; Child; Deferoxamine; Ferritins; Hearing L | 1990 |
Desferrioxamine and membrane oxidation: radical scavenger or iron chelator?
Topics: Anemia, Sickle Cell; Deferoxamine; Erythrocyte Membrane; Free Radicals; Humans; In Vitro Techniques; | 1989 |
[Treatment of post-transfusion iron overload by deferoxamine].
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Deferoxamine; Ferritins; Hemochromatosis; Humans; Tha | 1989 |
Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy.
Topics: Adolescent; Adult; Anemia, Aplastic; Anemia, Sickle Cell; Catheterization, Central Venous; Deferoxam | 1989 |
High-dose intravenous chelation therapy with deferoxamine.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Deferoxamine; Ferritins; Humans; Infusion | 1989 |
Non-transferrin-bound iron in long-term transfusion in children with congenital anemias.
Topics: Adolescent; Adult; Anemia, Hemolytic, Congenital; Anemia, Sickle Cell; Anemia, Sideroblastic; Bindin | 1986 |
Cardiovascular adaptations to transfusion/chelation therapy of homozygote sickle cell anemia.
Topics: Adaptation, Physiological; Adolescent; Adult; Anemia, Sickle Cell; Aorta, Abdominal; Blood Flow Velo | 1988 |
Nontransferrin-bound serum iron in thalassemia and sickle cell patients.
Topics: Adult; Anemia, Sickle Cell; Chromatography, Ion Exchange; Deferoxamine; Electrophoresis, Polyacrylam | 1986 |
Sickle cell membranes and oxidative damage.
Topics: Anemia, Sickle Cell; Antioxidants; Ascorbic Acid; Deferoxamine; Erythrocyte Membrane; Erythrocytes, | 1986 |
[Desferal test in the diagnosis of hemosiderosis in patents with hemoglobinopathies].
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Child; Child, Preschool; Deferoxamine; Female; Hemoglo | 1971 |
Diagnosis of iron storage disease with desferrioxamine (Desferal test).
Topics: Anemia, Macrocytic; Anemia, Sickle Cell; Deferoxamine; Female; Hemochromatosis; Hemosiderosis; Human | 1964 |
[Significance of disorders of hemoglobin synthesis for the clinical practice].
Topics: Anemia, Macrocytic; Anemia, Sickle Cell; Deferoxamine; Erythrocyte Aging; Erythropoiesis; Hematologi | 1967 |
The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
Topics: Adolescent; Anemia, Sickle Cell; Biopsy; Child; Deferoxamine; Female; Hemochromatosis; Hemosiderosis | 1966 |